Biocat and Alira Health promote Startup Support Program 2024
On February 15, during Barcelona Health Innovation Week, there will be an information session on the training and applications will be accepted from interested companies. This year, the training is aimed at companies and projects in the advanced and emerging therapies sector.
Biocat and the international consultancy firm Alira Health are promoting the second annual Startup Support Program 2024, focusing on advanced and emerging therapies companies and projects. On February 15 at 6:30 pm, during Barcelona Health Innovation Week, there will be an information session and applications will be accepted from interested companies. Registration will remain open until April 10.
The program offers mentoring from an experienced team of consultants and designs a roadmap for market access, mainly in France, Germany, Italy, the United Kingdom and Spain, for companies focused on advanced therapies.
What does the program include?
The program includes 40 hours of mentoring over 4 weeks for 3 companies in the BioRegion, plus a kick-off meeting, in-depth analysis, guidance session on reimbursement claims, reviewing claims and additional consultations.
Plus, the selected startups can get:
- Review of internal information provided by the companies to gain an in-depth understanding of their product, goals and aspirations.
- Assessment of product maturity from a market access standpoint.
- Identifying and prioritizing critical gaps.
- Creating a top-notch market access roadmap with key activities based on gap analysis.
- Guidance and support for taking the next steps.
What methodology is used?
The 2024 Startup Support Program uses the maturity assessment methodology and the gap prioritization methodology, based on the documents and information provided by the company to identify their weaknesses and current maturity There are five phases:
- Internal documents: presentation of company information and portfolio.
- Internal meetings: assessment of maturity and other internal communication.
- Maturity tool: commercial strategy, overview of the disease the product targets, product value proposition and analysis of the competition.
- Maturity scoring: assessment and knowledge of market access maturity, identifying shortfalls in the market access strategy and the next steps to take.
- Prioritizing weaknesses: identifying market access risks.
The first edition of this training program finished in December, with participating companies Accure Therapeutics, D-Sight and AROMICS. “The program showed us the different dimensions of market access and how to address each one in order to valorize the program with investors and/or pharmaceutical companies,” the startups highlighted.
They also valued the training on market access and how it will help them in the future: “The training gave us a great overview of drug development and commercialization. We looked at aspects of the market that will help us negotiate licensing and investments in the future.”